Start-Up Previews (02/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Antibody Platforms," features profiles of arGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology. Plus these Start-Ups Across Health Care: BioMarker Strategies, BMEYE, Clear Catheter Systesm, Epicardial Technologies and Optibrium.
You may also be interested in...
Since the chest tubes used postoperatively to drain blood and fluid from around the patient's heart have a tendency to clog, surgeons often choose large tubes, which are often the most visible--and painful--reminder a patient has of his surgery. Clear Catheter Systems LLC is developing technology that has the potential to make heart-surgery recovery safer and perhaps less painful by using smaller diameter tubes and actively breaking up occluding material that can lead to serious complications.
Targeted cancer drugs are all the rage--and with good reason--but it remains challenging to accurately predict which patients will respond to them. BioMarker Strategies LLC has developed SnapPath, an ex vivo biomarker system that disperses solid tumor tissue in media. It then exposes live cells to growth factors and other stimuli to induce them to produce phosphoproteins and other ex vivo biomarkers to reveal the functional circuitry of the patient's tumor cells.
Nexfin from BMEYE BV is a noninvasive cardiovascular monitoring system that not only checks blood pressure--heartbeat to heartbeat--but also provides physicians with cardiac output and full hemodynamics data, measured with a finger cuff connected to a wrist unit, which is linked to a monitor.